The platelet-rich plasma (PRP) aggregation assay is a cornerstone laboratory technique for evaluating platelet function in hemostasis, thrombosis research, antiplatelet therapy monitoring, and regenerative medicine. This article provides a comprehensive technical overview of PRP aggregation testing, including sample requirements, measurable parameters, analytical methods, and practical applications. Whether performed in hospital coagulation laboratories or accredited third-party laboratories, PRP aggregation testing delivers critical insight into hemostatic competence and the functional quality of platelet-based preparations.
Technical Overview
The platelet-rich plasma (PRP) aggregation assay measures the capacity of platelets to activate and aggregate in response to physiologic or pharmacologic stimuli known as agonists. PRP is obtained from anticoagulated whole blood through differential centrifugation, which concentrates platelets to approximately two to four times their baseline concentration while preserving their native, unactivated state. When a defined agonist is introduced under controlled temperature and stirring conditions, activated platelets expose glycoprotein receptors, bind fibrinogen or von Willebrand factor, and form aggregates. The assay quantifies this response in real time, producing a characteristic aggregation curve that reflects platelet reactivity.
Light transmission aggregometry (LTA), first described by Born in 1962, remains the historical gold standard for platelet function testing and is the method most closely associated with PRP-based analysis. Complementary techniques such as impedance aggregometry and flow cytometric activation assays extend the analytical reach of PRP testing, particularly for whole-blood workflows, thrombocytopenic samples, and point-of-care antiplatelet monitoring. Methodological harmonization is supported by guidance documents such as CLSI H58 (Platelet Function Testing by Aggregometry), while device-related blood-contact studies may reference ISO 10993-4 for hemocompatibility evaluation.
- Primary purpose: quantitative assessment of platelet activation and aggregation capacity
- Core principle: stimulation of platelets in PRP with standardized agonists and real-time measurement of the aggregation response
- Key outputs: maximum aggregation percentage, aggregation slope, lag phase, and area under the aggregation curve
- Typical platforms: optical (turbidimetric) aggregometers, impedance aggregometers, and flow cytometers
Testing Samples
Citrated Whole Blood
Venous blood is collected via atraumatic venipuncture into tubes containing 3.2% trisodium citrate at a 9:1 blood-to-anticoagulant ratio. The first 2 to 3 mL of drawn blood should be discarded to exclude tissue factor–activated platelets. Samples must be maintained at 15 to 25 °C, gently mixed, and processed promptly, as platelet responsiveness declines measurably beyond two to four hours after collection.
Platelet-Rich Plasma (PRP)
PRP is prepared by soft-spin centrifugation of citrated whole blood, typically at low relative centrifugal force, to sediment erythrocytes and leukocytes while retaining platelets in the plasma fraction. The platelet count of the PRP fraction should be verified with a hematology analyzer and, where required, standardized by dilution with autologous platelet-poor plasma to a target concentration, commonly 200 to 300 × 10⁹/L, to reduce inter-sample variability.
Platelet-Poor Plasma (PPP)
PPP is generated by high-speed centrifugation of the residual blood fraction and serves as the 100% transmission (or zero-platelet) reference baseline in optical aggregometry. Matching PRP and PPP from the same donor is essential for accurate curve normalization.
Control Materials
Because platelets cannot be lyophilized without losing function, analytical quality control relies on parallel testing of blood from healthy reference donors recruited under standardized conditions, ideally free of platelet-active medications for at least 7 to 14 days. Documented normal and abnormal response patterns from reference donors are used to verify assay performance on each testing day.
Testing Items
A complete PRP aggregation workup characterizes the aggregation response across a panel of agonists that probe distinct platelet activation pathways. The panel is selected according to the clinical or research question and is interpreted as a pattern rather than as isolated values.
- ADP-induced aggregation: evaluates the P2Y1 and P2Y12 receptor pathways; sensitive to thienopyridine-class antiplatelet drugs
- Arachidonic acid–induced aggregation: evaluates the cyclooxygenase pathway; sensitive to aspirin effect
- Collagen-induced aggregation: probes adhesion-mediated activation and thromboxane generation
- Epinephrine-induced aggregation: assesses amplification of activation through alpha-adrenergic platelet receptors
- Ristocetin-induced aggregation (agglutination): evaluates glycoprotein Ib–IX–V interaction with von Willebrand factor
- Thrombin receptor activating peptide (TRAP) aggregation: probes protease-activated receptor (PAR) signaling
- Quantitative curve parameters: maximum aggregation percentage, initial slope, lag time, and area under the curve
- Supplementary attributes: PRP platelet count, hematocrit of source blood, and visual assessment for hemolysis, lipemia, or premature clotting
Testing Methods
Light Transmission Aggregometry (LTA)
In LTA, PRP is warmed to 37 °C in a cuvette containing a stir bar rotating at approximately 1,000 to 1,200 rpm. PPP defines the 100% transmission baseline and unstimulated PRP the 0% baseline. Upon addition of agonist, platelet aggregates form, allowing more light to pass through the sample; the increase in light transmission is recorded continuously as an aggregation tracing. Maximum aggregation, slope, and lag phase are derived from the curve. LTA provides the richest diagnostic pattern information but demands meticulous pre-analytical control and adequate platelet counts.
Impedance Aggregometry
Impedance (whole-blood or PRP) aggregometry measures the increase in electrical impedance between electrodes as activated platelets adhere to and aggregate on the metal surface. The method is tolerant of lower platelet counts, requires no plasma optical clarity, and is well suited to monitoring antiplatelet therapy and to near-patient testing environments. Results are typically reported in aggregation units or area under the curve derived from the impedance tracing.
Flow Cytometric Activation Assays
Flow cytometry quantifies platelet activation markers such as P-selectin (CD62P) expression, activated glycoprotein IIb/IIIa conformation, and phosphatidylserine exposure using fluorescently labeled antibodies. Only small sample volumes are required, platelets are analyzed individually at near-physiologic concentrations, and the technique is particularly valuable for thrombocytopenic specimens or mechanistic studies.
Pre-Analytical and Quality Controls
- Medication washout: aspirin 10 to 14 days, P2Y12 inhibitors approximately 7 days, NSAIDs 3 to 5 days, unless the objective is therapeutic drug monitoring
- Fasting or light, low-fat meal recommended to avoid lipemic interference with optical measurements
- Sample holding time limited to 2 to 4 hours at room temperature; refrigeration is prohibited because cold activates platelets
- Correct citrate fill volume verified, as underfilled tubes alter the anticoagulant ratio and calcium availability
- Parallel testing of healthy reference donor blood to confirm agonist and instrument performance
Applications
PRP aggregation testing supports a broad spectrum of clinical diagnostic, therapeutic monitoring, and research applications. Its diagnostic power lies in pattern interpretation across the agonist panel, which can distinguish specific inherited and acquired platelet function disorders.
- Diagnosis of inherited platelet function disorders: Glanzmann thrombasthenia shows absent aggregation to all agonists except a normal ristocetin response; Bernard-Soulier syndrome shows impaired ristocetin agglutination; storage pool and secretion defects show diminished second-wave aggregation
- Evaluation of unexplained mucocutaneous bleeding, prolonged bleeding time, or suspected qualitative platelet defects
- Monitoring of antiplatelet therapy, including aspirin effect, P2Y12 inhibition, and laboratory assessment of high on-treatment platelet reactivity
- Perioperative planning for patients on antiplatelet agents or with a history of perioperative bleeding
- Quality control of PRP preparations intended for regenerative medicine and orthobiologic use, confirming that concentrated platelets retain the ability to activate, aggregate, and release granule contents
- Hemocompatibility and thrombogenicity evaluation of blood-contacting medical devices in accordance with ISO 10993-4
- Pharmaceutical research on platelet-targeting drugs, agonists, antagonists, and pro-hemostatic agents
FAQ
Why is sodium citrate used instead of heparin or EDTA for PRP aggregation testing?
Sodium citrate reversibly chelates calcium at a concentration that preserves platelet responsiveness, allowing agonists to restore free calcium and trigger aggregation during the assay. EDTA irreversibly chelates calcium and dissociates platelet glycoprotein complexes, while heparin can directly activate or inhibit platelets, making both unsuitable for functional aggregometry.
What constitutes a normal aggregation response?
Laboratory-specific reference intervals apply, but healthy donors typically achieve maximum aggregation above approximately 60 to 70% with strong agonists such as ADP at high concentration, collagen, arachidonic acid, and TRAP. Interpretation always considers the entire agonist panel pattern, the patient's medication history, and concurrent control donor results.
How long are samples stable for PRP aggregation testing?
For light transmission aggregometry, testing should be completed within 2 to 4 hours of blood collection, with samples held at room temperature without agitation. Impedance aggregometry generally permits a similar or slightly extended window, but every laboratory should validate its own stability limits as part of its quality system, consistent with ISO 15189 requirements for clinical laboratories.
Can the assay detect the effect of aspirin and clopidogrel?
Yes. Aspirin typically abolishes arachidonic acid–induced aggregation and converts ADP responses to a single reversible wave, while P2Y12 inhibitors markedly reduce ADP-induced aggregation with preserved ristocetin and TRAP responses. When drug effect is the analyte of interest, no washout period is required.
How is PRP aggregation testing relevant to regenerative medicine?
PRP products used in orthopedics, wound healing, and aesthetic medicine vary widely in platelet concentration and functional integrity. Aggregation and activation testing verifies that the processed platelets remain viable and capable of degranulation and growth factor release, providing an essential functional quality attribute that complements platelet counting alone.